Archive · 21 Jun 2025
ZeroHarm Expands into GCC Markets, Eyes ₹150 Crore Revenue
ZeroHarm Sciences, a health product company from India, is growing quickly and expanding its business!
They are planning to grow in the Middle East, especially in places like the UAE.
They are doing well in the United States.
They are aiming to make a lot of money this year.
They are already doing well and making a good profit.
Their goal is to sell more products to more people.
ZeroHarm Sciences is expanding into GCC markets, including the UAE.
The company aims for ₹150 crore in gross revenue in the current fiscal year.
ZeroHarm experienced a 10x revenue growth over the past two years.
The company's EBITDA margin is approximately 20%.
US revenue contributes nearly 30% of ZeroHarm's overall revenue.
- Who
- ZeroHarm Sciences, a clean-label nutraceutical company.
- What
- ZeroHarm Sciences is accelerating its global expansion into the GCC markets.
- When
- The company is aiming for ₹150 crore in gross revenue in the current fiscal year.
- Where
- Focusing expansion in GCC markets, including the UAE.
- Why
- To expand its global footprint and market share.
- Revenue Target
- ₹150 crore (FY 2025)
- Revenue Growth (past 2 years)
- 10x
- EBITDA Margin
- ~20%
- Last Fiscal Year Gross Revenue
- ₹71 crore
- Exit ARR
- ₹90 crore
- US Revenue Contribution
- 30%
